Dabrafenib and its potential for the treatment of metastatic melanoma, Drug Des Devel Ther, vol.6, pp.391-405, 2012. ,
Mutations of the BRAF gene in human cancer, Nature, vol.7, issue.6892, pp.949-954, 2002. ,
DOI : 10.1016/S0960-9822(97)70094-0
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients, Annals of Oncology, vol.13, issue.8, pp.1691-1697, 2013. ,
DOI : 10.1016/S1470-2045(12)70269-3
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma, The Oncologist, vol.18, issue.3, pp.314-322, 2013. ,
DOI : 10.1634/theoncologist.2012-0333
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-819, 2010. ,
DOI : 10.1056/NEJMoa1002011
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, The Lancet Oncology, vol.15, issue.3, pp.323-332, 2014. ,
DOI : 10.1016/S1470-2045(14)70012-9
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study, The Lancet Oncology, vol.15, issue.4, pp.436-444, 2014. ,
DOI : 10.1016/S1470-2045(14)70051-8
Survival in BRAF V600???Mutant Advanced Melanoma Treated with Vemurafenib, New England Journal of Medicine, vol.366, issue.8, pp.707-714, 2012. ,
DOI : 10.1056/NEJMoa1112302
Cutaneous Adverse Events during Vemurafenib Therapy, Journal of Cutaneous Medicine and Surgery, vol.30, issue.4, pp.223-228, 2014. ,
DOI : 10.1007/s40265-013-0049-8
The European Medicines Agency review of vemurafenib (Zelboraf??) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use, European Journal of Cancer, vol.49, issue.7, pp.1654-1661, 2013. ,
DOI : 10.1016/j.ejca.2013.01.015
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study, Journal of the American Academy of Dermatology, vol.67, issue.6, pp.1265-1272, 2012. ,
DOI : 10.1016/j.jaad.2012.04.008
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study, European Journal of Cancer, vol.50, issue.3, pp.611-621, 2014. ,
DOI : 10.1016/j.ejca.2013.11.002
Dermatological approach to vemurafenib skin toxicity: a single centre experience, G Ital Dermatol Venereol, 2014. ,
Cutaneous effects of BRAF inhibitor therapy: a case series, Annals of Oncology, vol.29, issue.5, pp.530-537, 2013. ,
DOI : 10.1007/s10637-010-9567-3
RASopathic Skin Eruptions during Vemurafenib Therapy, PLoS ONE, vol.167, issue.5, p.58721, 2013. ,
DOI : 10.1371/journal.pone.0058721.g012
Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients., Journal of the European Academy of Dermatology and Venereology, vol.30, issue.1, pp.61-68, 2015. ,
DOI : 10.1200/JCO.2011.41.1660
Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas, British Journal of Dermatology, vol.21, issue.4, pp.934-938, 2013. ,
DOI : 10.1093/annonc/mdp472
Vemurafenib-Induced DRESS, JAMA Dermatology, vol.149, issue.10, pp.1242-1243, 2013. ,
DOI : 10.1001/jamadermatol.2013.5278
URL : http://archderm.jamanetwork.com/data/journals/derm/928256/dlo130030.pdf
N??crolyse ??pidermique toxique au vemurafenib, Annales de Dermatologie et de V??n??r??ologie, vol.141, issue.3, pp.215-218, 2014. ,
DOI : 10.1016/j.annder.2013.10.054
Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma, British Journal of Dermatology, vol.69, issue.4, pp.997-999, 2014. ,
DOI : 10.1016/j.jaad.2013.05.002
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities, British Journal of Dermatology, vol.30, issue.Suppl., pp.987-994, 2012. ,
DOI : 10.1200/JCO.2011.41.1660
Severe cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP or overlap reaction?, Journal of the European Academy of Dermatology and Venereology, vol.30, issue.1, 2014. ,
DOI : 10.1111/jdv.12685
Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis, British Journal of Dermatology, vol.149, issue.5, pp.1454-1455, 2015. ,
DOI : 10.1111/jdv.12685
Paradoxical oncogenesis: are all BRAF inhibitors equal?, Pigment Cell & Melanoma Research, vol.30, issue.5, pp.611-615, 2013. ,
DOI : 10.1200/JCO.2011.41.1660
The innate immune system in delayed cutaneous allergic reactions to medications, Current Opinion in Allergy and Clinical Immunology, vol.11, issue.4, pp.292-298, 2011. ,
DOI : 10.1097/ACI.0b013e3283489c2c
status in patients receiving panitumumab monotherapy, Cancer, vol.25, issue.7, pp.1544-1554, 2009. ,
DOI : 10.1007/978-94-017-0233-1